Stockholders' Equity (Tables)

3 Months Ended

Oct. 31, 2017

Stockholders' Equity Note [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The amounts of share-based compensation expense recognized in the periods presented are as follows:

	Three months ended October 31,
	2017		2016
Stock options	$	202	$	146
Restricted stock		3		5
	$	205	$	151

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

	Three months ended October 31,
	2017		2016
Cost of clinical laboratory services	$	—	$	2
Selling, general and administrative		205		149
	$	205	$	151

Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes stock option activity during the three month period ended October 31, 2017:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2017		2,130,995		$	4.26
Awarded		—		$	—
Exercised		(487,106	)	$	3.03			$	4,940
Cancelled or expired		(19,334	)	$	5.92
Outstanding at end of period		1,624,555		$	4.62		2.8 years	$	12,313
Exercisable at end of period		903,868		$	3.39		1.6 years	$	5,838

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]

A summary of the activity pursuant to the Company’s unvested restricted stock awards for the three months ended October 31, 2017 is as follows:

	Awards			Weighted Average Award Price
Outstanding at July 31, 2017		7,436		$	4.45
Awarded		—			—
Vested		(1,001	)	$	(4.84	)
Forfeited		—			—
Unvested at end of period		6,435		$	3.85